Can a Self-Image workshop help rheumatic disease patients feel better about themselves?
NCT ID NCT07170826
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a therapeutic education program designed to improve self-image and self-esteem in adults with chronic inflammatory rheumatic diseases like rheumatoid arthritis and spondyloarthritis. Sixty participants will complete questionnaires and interviews before and after the program. The goal is to see if these workshops, which are already used in cancer and obesity care, can help people with rheumatic conditions feel more positive about their bodies and themselves.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- therapeutic education program (workshops and interviews focused on self-image)
- What this could lead to
- If it works, this program could become a standard part of care to help patients with chronic rheumatic diseases feel better about themselves.
- What could go wrong
- This is a small, early-stage study with only 60 participants, so results may not apply to everyone. The program is added to usual care, so any benefit may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2025
An estimate. Start dates often move.
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The target population will consist of patients with RIC (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis) participating in the ETP programme
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Suffering from chronic inflammatory rheumatism (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis) * Having agreed to follow the therapeutic education programme offered by the department as part of routine care * Not opposed to participating in the research Exclusion Criteria: * People who do not speak or read French * Current pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic inflammatory rheumatic diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Cochin - Service de rhumatologie -27 rue du Faubourg St Jacques
Paris, Île-de-France Region, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new ankle? researchers track 400 people with an implant meant to restore movement
- Can a Job-Focused rehab program keep arthritis patients employed?
- Can an oral drug calm psoriatic arthritis? phase 3 trial puts deucravacitinib to the test
- Do rheumatic diseases quietly damage the Eye's oil glands?
- Hidden kidney damage may lurk in rheumatoid arthritis patients
- Can a new injection calm rheumatoid arthritis? an early trial puts ZB002 to the test